JO
RARE icon

John Overdeck’s Ultragenyx Pharmaceutical RARE Stock Holding History

John Overdeck’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,000
Closed -$281K – 3246
2016
Q4 		$281K Buy
+4,000
New +$284K ﹤0.01% 2778

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's RARE Position: Q2 2026 in Review

John Overdeck increased its Ultragenyx Pharmaceutical (RARE) stake by 64% in Q2 2026, buying an estimated $35.2M and bringing the position to 3,621,200 shares worth $121M. The position accounts for 0.09% of the portfolio, ranked #258.

John Overdeck first reported a position in RARE in Q1 2015 and has held it in 28 quarters since. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • John Overdeck held 3,621,200 shares of Ultragenyx Pharmaceutical worth $121M as of Q2 2026.
  • John Overdeck bought 1,415,380 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $35.2M.
  • Ultragenyx Pharmaceutical made up 0.09% of John Overdeck's portfolio in Q2 2026, its #258 holding.
  • John Overdeck first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 28 quarters since.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.